Emapalumab, a drug that suppresses the action of interferon-gamma, has already been approved for people who are genetically predisposed to a cytokine storm. In addition to this, certain drugs originally designed to treat rheumatoid arthritis, such as anakinra and tocilizumab, also demonstrated promising efficacy in taming the dangerous cytokine storms.